Loading...
Derniers dépôts
-
Emeline Tabouret, François Bertucci, Jean-Yves Pierga, Thierry Petit, Christelle Levy, et al.. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7 (14), pp.18531-18540. ⟨10.18632/oncotarget.7612⟩. ⟨hal-03623733⟩
-
Anne Patsouris, Kadija Diop, Olivier Tredan, Daniel Nenciu, Anthony Gonçalves, et al.. Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. European Journal of Cancer, 2021, 159, pp.283-295. ⟨10.1016/j.ejca.2021.09.028⟩. ⟨hal-04522229⟩
-
-
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, et al.. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. Journal of Thoracic Oncology, 2023, 18 (5), pp.576-586. ⟨10.1016/j.jtho.2022.12.018⟩. ⟨hal-04519993⟩
-
S. Peters, A. Scherpereel, R. Cornelissen, Y. Oulkhouir, L. Greillier, et al.. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology, 2022, 33 (5), pp.488-499. ⟨10.1016/j.annonc.2022.01.074⟩. ⟨hal-04085315⟩
-
Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩
-
-
-
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, et al.. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. Journal of Thoracic Oncology, 2023, 18 (5), pp.576-586. ⟨10.1016/j.jtho.2022.12.018⟩. ⟨hal-04176638⟩
-
Pauline Marolleau, David Tougeron, Benoit Allignet, Romain Cohen, David Sefrioui, et al.. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study. International Journal of Cancer, 2023, ⟨10.1002/ijc.34636⟩. ⟨hal-04154476⟩
-
-
Gilles Houvenaeghel, Alexandre De Nonneville, Monique Cohen, Jean-Marc Classe, Fabien Reyal, et al.. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. European Journal of Cancer, 2022, 176, pp.58-69. ⟨10.1016/j.ejca.2022.08.027⟩. ⟨hal-04084967⟩
-
Lionel Perrier, Frederic Balusson, Magali Morelle, Joël Castelli, Juliette Thariat, et al.. Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial. Radiotherapy & Oncology, 2024, Radiotherapy and Oncology : Journal of the European Society For Therapeutic, 193, pp.110116. ⟨10.1016/j.radonc.2024.110116⟩. ⟨hal-04444231⟩
-
Victor Sérénon, Philippe Rouanet, Diane Charleux-Muller, Clarisse Eveno, Karine Poirot, et al.. Iatrogenic ureteral injury during colorectal surgery has a significant impact on patient outcomes: a French multicentric retrospective cohort study. Colorectal Disease, 2023, ⟨10.1111/codi.16630⟩. ⟨hal-04113776⟩
-
Sara A Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, et al.. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. The Lancet, 2023, 401 (10371), pp.105-117. ⟨10.1016/s0140-6736(22)02420-5⟩. ⟨hal-04581303⟩
-
-
Alice Rousseau, Christel Stien, Jean Gouriou, jean-marc bordy, Guillaume Boissonnat, et al.. End-to-end quality assurance for stereotactic radiotherapy with Fricke-Xylenol orange-Gelatin gel dosimeter and dual-wavelength cone-beam optical CT readout. Physica Medica European Journal of Medical Physics, 2023, 113, 102656 (12 p.). ⟨10.1016/j.ejmp.2023.102656⟩. ⟨cea-04563755⟩
-
Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, et al.. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, pp.22524. ⟨10.1038/s41598-023-49887-4⟩. ⟨hal-04543900⟩
-
Anna Gueiderikh, Thomas Sarrade, Youlia M. Kirova, Brigitte de la Lande, Florent de Vathaire, et al.. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Frontiers in Oncology, 2023, 13, ⟨10.3389/fonc.2023.1199043⟩. ⟨hal-04195134⟩
-
Justine Gantzer, Maud Toulmonde, François Séverac, Ali N. Chamseddine, Celine Charon-Barra, et al.. PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent. Cancer, 2024, ⟨10.1002/cncr.35277⟩. ⟨hal-04533834⟩